Clinical Trial Aims to Optimize the Transition from Pediatric to Adult Care for Adolescents with Type 1 Diabetes

JDRF Canadian Clinical Trial Network launches first randomized controlled trial of a structured transition clinic

London, Ontario (April 20, 2012) – JDRF Canadian Clinical Trial Network (JDRF CCTN) is pleased to announce the launch of the Structured Transition from Pediatric Care to Adult Care in Type 1 Diabetes Trial (Transition Trial). Led by Dr. Cheril Clarson at the Children’s Hospital, London Health Sciences Centre (LHSC), and Dr. Tamara Spaic at St. Joseph’s Health Care, London, the study will be the first randomized controlled trial of a structured transition clinic that incorporates a dedicated coordinator to aid in the transition process. The goal of the study is to improve clinic adherence and health outcomes by closing the gap in the care of this population at a vulnerable time.

Adolescence is a period in life associated with many challenges. For patients with chronic diseases – such as type 1 diabetes (T1D) – this life stage is complicated by the daily demands of disease management. One of the major changes that occur for adolescents living with T1D is the transition from pediatric to adult medical care.1-3 Diabetes control may significantly deteriorate during adolescence due to multiple factors, including: physiological insulin resistance (caused by the hormonal changes of puberty), psychosocial distress, risk taking behaviour, intentional insulin omission (due to attention seeking or as a means of weight loss), or eating disorders.4,5

“Adolescence is a time of many changes. It can be challenging for anyone, but for individuals with type 1 diabetes, it is a particularly vulnerable period,” said Dr. Clarson, pediatric endocrinologist, Children’s Hospital, LHSC. “The Transition Trial will determine if a structured transition program for adolescents and young adults with type 1 diabetes improves diabetes clinic attendance and management, as well as glycemic control. Results of the Transition Trial may also be translatable to young adults with other chronic conditions at the time of transition, and may serve to inform clinical practice guidelines.”

In Canada, up to 41 per cent of T1D patients drop out of adult medical care in the first year of transition and 46 per cent report difficulties with the transition process.6 Consequences range from poorer glucose control,7,8-11 higher incidence of retinopathy8 and nephropathy,12 and greater hospitalization rates.11 Pilot studies have shown that transition support programs can improve the quality of care in young adults.13

“JDRF is committed, as we always have been, to delivering a cure for type 1 diabetes and its complications for the more than 300,000 Canadians living with the disease,” said Andrew McKee, president and CEO of JDRF Canada. “We are also focused on developing better treatments that transform the way people with type 1 diabetes treat the disease today in order to help them live healthier lives, now and in the future.”

"Our government’s support to JDRF is helping to bring new cures and therapies for diabetes to the marketplace, which is shaping a better future for all Canadians,” said Ed Holder, Member of Parliament, London West, on behalf of the Honourable Gary Goodyear, Minister of State for the Federal Economic Development Agency for Southern Ontario (FedDev Ontario). “We are pleased that our investment continues to strengthen Canada’s science, technology, and innovation advantages, and create high value jobs throughout our South Western Ontario region."

The Transition Trial is a multi-centre randomized controlled trial with collaboration between pediatric and adult diabetes centres in several locations throughout Ontario, including: London (Children’s Hospital, LHSC and St. Joseph’s Health Care); Ottawa (Children’s Hospital of Eastern Ontario and The Ottawa Hospital); and Mississauga (Trillium Health Centre). A minimum of 188 participants with TID aged between 17 and 20 years will be randomly assigned in a 1:1 ratio to either a structured transition program that will span 18 months, or a standard diabetes care program. Participants will be seen in the pediatric care setting for six months, and then transferred to the adult care setting where they will be seen for one year. Lastly, there will then be a one-year follow-up period for outcome assessment.


About JDRF
JDRF is the leading global organization focused on T1D research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF is now the largest charitable supporter of T1D research. The goal of JDRF research is to improve the lives of all people affected by T1D by accelerating progress on the most promising opportunities for curing, better treating,
and preventing T1D. JDRF collaborates with a wide spectrum of partners who share this goal.

Since its founding in 1970 (1974 in Canada), JDRF has awarded more than $1.6 billion to diabetes research. Past JDRF efforts have helped to significantly advance the care of people with this disease, and have expanded the critical scientific understanding of T1D. JDRF will not rest until T1D is fully conquered. For more information, please visit www.jdrf.ca.

About JDRF Canadian Clinical Trial Network
Created in partnership with the Government of Canada, funding for JDRF CCTN came from a commitment of $20 million by FedDev Ontario, with an additional $13.9 million contribution from JDRF. The $33.9 million investment will help accelerate the testing of new technologies and treatments for Canadians and individuals around the world living with T1D and its complications.

JDRF CCTN is a groundbreaking effort to accelerate solutions for the management, care, and cure of T1D. JDRF CCTN is currently developing several high-profile clinical trials, in association with leading diabetes researchers at partner universities and medical centres in southern Ontario. The goal is to position southern Ontario as an international hub for diabetes translational research, innovation, and commercialization of new therapeutics and enabling technologies. For more information, please visit www.jdrf.ca/cctn.

For more information about the Transition Trial, or to schedule an interview, please contact:
Jennifer Dolan
JDRF Canadian Clinical Trial Network
647.789.2012
jdolan@jdrf.ca

Lets turn type one into type none